A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 249 participants.
Also called NCT07647133
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 249 participants
- Registry
-
NCT07647133
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07647133. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-15 (anticipated); primary completion 2027-10-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- SAL0140 Tablets
- Intervention (Drug)
- SAL0140 Tablets
- Intervention (Drug)
- SAL0140 placebo
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct07647133- Content hash
8da8ae5506e1c383fa005417c7d3b1771a1a347f3b848e127d5423901711497f